Amylyx (AMLX) Stock Soars 45% as Avexitide Trial Shows 55% Reduction in Hypoglycemia Episodes

Amylyx (AMLX) stock jumped 45% after avexitide demonstrated 55% reduction in post-bariatric hypoglycemia episodes. Company launches $350M offering.

The post Amylyx (AMLX) Stock Soars 45% as Avexitide Trial Shows 55% Reduction in Hypoglycemia Episodes appeared first on Blockonomi.